150 results about "Drug action" patented technology

The invention provides a nanocrystalline composite oral ulcer film agent as well as a preparation method and application thereof. The nanocrystalline composite oral ulcer film agent comprises a waterproof backing layer and a drug-loading adhesion layer coated on the waterproof backing layer, the drug-loaded adhesion layer comprises a macromolecular hydrogen bond compound formed by a weakly acidic polymer and a nonionic proton receptor polymer, and a nanocrystalline drug. Compared with the prior art, the preparation method has the advantages that the polyacrylic acid polymer and the nonionic cellulose polymer interact to form IPC serving as an adhesion layer film-forming material, the nanocrystals are loaded into the adhesion layer film-forming material, the waterproof backing layer is coated with the adhesion layer film-forming material, and the oral ulcer film agent is prepared after drying and cutting. The obtained film agent has good comfort and adhesive power, shows good drug stability and permeation promotion performance, can be used as a carrier of an oral administration route, prolongs the drug action time and improves the curative effect. The preparation method of the film agent is simple and easy for industrial mass production.

The invention relates to the technical field of biological medicine, in particular to anti-acne hydrogel and a preparation method thereof. The anti-acne hydrogel is prepared from metal-polyphenol network nanoparticles and a hydrogel base material, the metal-polyphenol network nanoparticles comprise a first polyphenol compound, a second polyphenol compound and metal ions, the first polyphenol compound is a tannic acid compound, and the second polyphenol compound is a flavonoid compound; the hydrogel base material comprises a hydrophilic high-molecular polymer and a cationic polymer. The metal-polyphenol network nano-particles are creatively utilized, the anti-inflammatory and anti-oxidation activity of flavonoid compounds, the convergence and protein binding characteristic of tannin and the antibacterial activity of metal ions are integrated at the same time, and the vicious circle of acne can be intervened at the same time from multiple links of antibacterial, anti-inflammatory, anti-oxidation and keratinization adjustment; and the defect of single action target spot of the existing medicine is overcome.

The invention relates to a heart rehabilitation management method based on rehabilitation requirements. The method comprises the following steps: acquiring oxygen saturation time sequence data of a patient through wearable equipment, performing biological rhythm feature extraction on the data to construct a fluctuation model so as to capture a physiological cycle rule, and constructing a drug action factor based on a drug taking record to perform drug action calibration on original data so as to eliminate exogenous interference. Candidate time windows with consistent physiological statuses are screened through sliding window stability analysis; dynamic baseline calculation is performed on the candidate window based on long-term monitoring data to establish an individualized reference standard, when the dynamic baseline reaches the standard, the biological rhythm parameters and the drug action factors are fused to score and screen the time window, and finally, an individualized rehabilitation training scheme is generated in combination with physiological feature matching of a patient. Dynamic synergy of drug metabolism, physiological rhythm and historical baselines is achieved, the problem of physiological load imbalance caused by a static training plan is solved, and the rehabilitation efficiency is improved while the heart compensation risk is remarkably reduced.

The invention belongs to the technical field of computer biology, and relates to a lightweight drug-target interaction prediction method based on double pre-training language models. Downloading a protein information data set of required drug compounds and drug action targets from a public database; sending the protein sequence into an encoder to obtain a generated vector; the method comprises the following steps: labeling a compound sequence of a drug by using a tokenizer, pre-defining a corresponding relation between a compound sequence label and an integer, then converting into an integer value, and inputting the integer value into an encoder to generate a vector; splicing the class tokens to obtain a drug target pair, and feeding the drug target pair into an interaction head; and calculating an interaction probability between the two. According to the method, the drug pre-training language model and the protein pre-training language model are introduced at the same time, deep semantic coding is performed on the SMILES sequence and the amino acid sequence, molecular structure characteristics and protein sequence characteristics can be comprehensively captured, and the expression ability is remarkably enhanced.

The invention discloses a microfluidic multi-organ tumor chip targeted drug test AIGC system, and relates to the technical field of medical drug test information processing. The microfluidic multi-organ tumor chip targeted drug test AIGC system comprises a multi-omics data acquisition module for acquiring and preprocessing disturbance response data and dynamic expression data; the disturbance response pre-screening module is used for carrying out strength evaluation on drug action strength and reconstructing channel mapping; the characteristic space reconstruction module is used for performing action analysis on the whole medicine action state and dynamically adjusting a liquid medicine blending rule; the drug effect prediction module is used for predicting and evaluating the response degree of the organoid under the intervention of the specific drug and deducing the individualized drug effect intensity; and the feature augmentation self-closed loop module constructs a negative supervision signal and dynamically corrects a disturbance perception and feature embedding path. The problems that current multi-omics data is high in dimension, large in redundancy and large in noise, key features are difficult to extract under limited samples, and model generalization is difficult to maintain are solved.

This invention discloses an AfBPP-based active molecular probe for thiostreptin, its preparation, and its application, belonging to the field of chemical biology. This invention introduces a bifunctional tag integrating a photocrosslinking group (bisacrididine) and a bioorthogonal reactive group (alkynyl group) into the structure of thiostreptin. While retaining the original biological activity of the parent compound, it endows the probe with highly efficient probe function, solving the technical problem of target loss during washing and purification of traditional non-covalent probes. After target labeling, the probe can specifically connect to reporter groups such as fluorescein or biotin through click-chemical reactions, achieving efficient enrichment of drug targets. Combined with mass spectrometry analysis, it enables global identification of potential targets in cells or complex biological samples at the omics level, such as chemical proteomics, providing a powerful molecular tool for in-depth revelation of the potential targets and pharmacological mechanisms of thiostreptin.

The invention discloses a mitochondrial / lysosome dual-targeting viscosity response AIE probe as well as a preparation method and application thereof. According to the probe, tetraphenylethylene (TPE) is used as an AIE light-emitting framework, and two flexible side chains containing hydrophilic units are introduced by utilizing the excellent structural modifiability of the TPE. The tail end of each side chain is modified with a trimethylamine group, quaternary ammonium salt cations derived from the trimethylamine group have localized positive charges, and combination with water molecules can be enhanced through ion-dipole interaction, so that the water solubility and biocompatibility of the molecules are effectively improved. Based on the design, the invention provides the AIE polymer probe which is constructed by taking TPE as a core and taking an amphiphilic flexible chain as a functional unit. The probe can establish a three-dimensional linear relationship among drug action time-regional viscosity-fluorescence lifetime (t-eta-tau) by capturing fluorescence lifetime signals inside and outside cells, so as to realize visual detection and quantitative analysis of average viscosity change of mitochondria and lysosome in the mitochondrial autophagy process.

The invention discloses a precise regulation and control injection device for extraocular muscle toxin, and belongs to the technical field of medical instruments. The precise regulation and control injection device for extraocular muscle toxin comprises a microneedle assembly, a handle, a suction head and an injection regulation and control part, wherein the injection regulation and control part is used for controlling the microneedle assembly to be connected with the suction head. When the precise regulation and control injection device for the extraocular muscle toxin is used, the micro-needle assembly can be in suction connection with the suction head arranged at the tail end of the handle through adjustment of the injection regulation and control part, so that in the process that an operator injects the extraocular muscle toxin to a patient, it is ensured that a micro-needle does not deviate or loosen in the injection process, and the injection efficiency is improved. The precise positioning of an injection part is ensured; and the injection regulation and control part can regulate the action range of the microneedle on the microneedle assembly to be more concentrated, so that the concentration of the action range of the medicine and the accurate delivery of the medicine to the target muscle layer can be ensured, the out-of-control diffusion of the medicine is avoided, and the risk of penetrating through the sclera is reduced.

The invention relates to the technical field of biomedical materials and wound repair, and discloses a preparation method and application of 4 '-hydroxychalcone-loaded nanofiber hydrogel, the preparation method comprises the following steps: mixing 4'-hydroxychalcone and polylactic acid according to a mass ratio of 1: (6-12), and carrying out ultrasonic treatment to obtain 4 '-hydroxychalcone-loaded nanofiber hydrogel; preparing nanofibers containing 4 '-hydroxychalcone by adopting an electrostatic spinning technology; according to the present invention, the 4 '-hydroxychalcone-loaded nanofiber hydrogel has the following characteristics that the drug in the 4'-hydroxychalcone-loaded nanofiber hydrogel can be continuously released, and the cumulative release rate can achieve 70-85% within 72 h so as to maintain the stable drug action concentration on the wound surface; meanwhile, the nanofiber hydrogel has good water retention capacity, the water retention rate of the nanofiber hydrogel can reach 90-95%, a stable wet healing environment can be provided for the wound surface, and the wound surface repairing process is facilitated.

This invention discloses a method and system for evaluating the effectiveness of cardiac rehabilitation, relating to the field of medical and health technology. The method includes: acquiring physiological monitoring data, individualized parameter data, comorbidity data, multidrug therapy data, pharmacokinetic parameters, and pharmacodynamic interaction parameters of the target patient; generating baseline physiological index data without drug intervention based on the individualized parameter data and comorbidity data through a pre-set individualized cardiac response baseline model; calculating drug concentration based on multidrug therapy data and pharmacokinetic parameters; calculating comprehensive pharmacodynamic data by combining pharmacodynamic interaction parameters; generating predicted physiological data under multidrug intervention; subsequently obtaining purified physiological data through adaptive filtering and frequency domain decomposition; and finally generating a rehabilitation effect score through a pre-trained long short-term memory network model. Its beneficial effects include: distinguishing between drug interference and real cardiac function improvement, and improving the accuracy of rehabilitation assessment for patients undergoing multidrug therapy.

This invention relates to the application of mitochondrial extracts in reversing drug resistance in solid tumors. By combining mitochondrial extracts with chemotherapeutic drugs, the resistance of chemotherapeutic-resistant solid tumors to these drugs can be reversed. Compared to using mitochondrial extracts and chemotherapeutic drugs alone, this method effectively enhances drug efficacy, thereby overcoming chemotherapeutic resistance in solid tumors. This invention, through intervention with mitochondrial extracts in different chemotherapeutic-resistant solid tumor cell lines, has verified that the combined use of mitochondrial transplantation and chemotherapeutic drugs can reverse chemotherapeutic resistance, thereby improving the efficacy of chemotherapy and opening up the possibility of continued treatment for patients with advanced solid tumors who are resistant to chemotherapeutic drugs.

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

A method for maintaining a gene description dataset associated with a plurality of genes with respect to a given disease, wherein the gene description dataset is a human- comprehensible text-based dataset generated by a Large Language Model (LLM); maintaining a dataset of drug mechanisms of action (MOAs) associated with a plurality of drugs; embedding the gene descriptions and the MOAs into high-dimensional vectors using a text embedding technique to generate gene description vectors and MOA vectors; calculating distances between the gene description vectors and the MOA vectors to generate distance scores; and ranking the drugs for the given disease based on an aggregated distance score between the MOA vectors and the vectors of genes associated with the given disease.

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

The application provides a preparation method and application of resveratrol-polylactic acid microspheres, and relates to the technical field of biological agents, quantitative resveratrol is dissolved in methanol as O1 phase; quantitative polylactic acid is dissolved in an oil phase solution (ethyl acetate, dichloromethane, trichloromethane) as O2 phase; ammonium bicarbonate, sodium bicarbonate, sodium chloride and hydrogen peroxide are used as a porogen; O1 phase, O2 phase and the porogen solution are subjected to ultrasonic emulsification to obtain O / O primary emulsion; the O / O primary emulsion is added to a polyvinyl alcohol aqueous solution under stirring to obtain O / O / W multiple emulsion; the obtained O / O / W multiple emulsion is subjected to mechanical stirring to remove the oil phase solution in the O / O / W multiple emulsion, and then is subjected to standing, centrifugation, washing, drying and the like to obtain resveratrol-polylactic acid microspheres with uniform size. The resveratrol-polylactic acid microspheres of the application break through the bottleneck of poor water solubility of resveratrol, can effectively prolong the drug action time, and have good antibacterial effect.

The present disclosure is directed to systems and methods for analyzing drug-drug and gene-drug interactions for a user and providing recommendations accordingly. The systems and methods can utilize a database comprising a list of genes are associated with a plurality of drugs based on clinical relevance of the gene to the actions of the plurality of drugs. The systems and methods can include recommending alternative drugs to users based on any identified problematic drug-drug or gene-drug interactions.

The invention discloses an AI intervention analysis method for diabetic renal interstitial fibrosis, and relates to the technical field of biologication.The method comprises the following specific steps of sample collection and multi-omics data acquisition, specifically, kidney tissue samples of diabetic renal interstitial fibrosis patients before and after the diabetic renal interstitial fibrosis patients use glucose kidney health intervention and kidney tissue samples of healthy contrasts are collected; respectively acquiring epigenetic data and single-cell gene expression data, preprocessing, and integrating to construct a comprehensive data set; by combining the AI technology and the high-throughput epigenetic detection technology, the epigenetic modification change on a TGF-beta1 / Smads signal path in the process of intervening diabetic renal interstitial fibrosis by the Sushenkang can be deeply analyzed; a brand-new perspective is provided for understanding the occurrence mechanism of the diabetic renal interstitial fibrosis disease and the drug action mechanism of the TGF-beta1 / Smads pathway, epigenetic data is deeply mined through AI, and the specific mechanism of the TGF-beta1 / Smads pathway related gene expression affected by the TGF-beta1 / Smads pathway through epigenetic regulation is shown.

This invention provides a drug interaction prediction method based on a bidirectional cross-view attention network, belonging to the field of drug interaction prediction technology. The method first constructs a Morgan fingerprint similarity view of the drug, an original DDI view, and a multi-scale diffusion view based on personalized PageRank. Then, a graph convolutional network with shared weights is used to co-encode the multiple views, generating a unified drug embedding representation. Finally, a bidirectional cross-view attention mechanism is used to achieve fine-grained interaction and alignment between the structural and attribute views, and interaction prediction is completed via a multilayer perceptron. This invention effectively alleviates the sparsity problem of the DDI network through multi-scale topology enhancement and achieves complementary enhancement between views using bidirectional cross-view attention, significantly improving the accuracy and generalization ability of drug interaction prediction. It can provide reliable technical support for drug development screening and clinical combined drug safety assessment.

The application discloses a medicine patch with gradient effect on human body, which comprises, from outside to inside, a back layer, a heating layer and a solid medicine layer, wherein the solid medicine layer is provided with solid medicine A; and further comprises a medicine liquid cavity for sealing liquid medicine B; when used, the medicine patch is attached to the human body for a set time, the medicine liquid cavity can be opened and the liquid medicine B can flow into the solid medicine layer; the solid medicine A can preliminarily treat related diseases under the action of heating, and the liquid medicine B is added in a progressive manner after the set time; the medicine patch has the gradient treatment requirement and the treatment effect, and can further drive the residual effect of the solid medicine B to continuously act on the affected area, improve the utilization rate of the medicine, and make the treatment medicine more targeted; thus, the traditional inertial thinking of the medicine patch is changed, interval medicine for treatment is made possible, the medicine effect is improved, and the foundation for the final treatment effect is laid.

The invention discloses a dual-channel drug delivery treatment system for open-angle glaucoma night intraocular hypertension, and relates to the technical field of medical instruments and clinical assistance. The system comprises a central control module, a time window control module, an intelligent double-medicine-bin medicine feeding module, a user interaction module, a data management and analysis module, a communication module, a safety and self-checking module and a power supply and management module. According to the invention, through the time window control module, the traditional morning administration is changed into night administration or individualized administration before intraocular pressure peak, the synchronization of the drug action peak and the night intraocular pressure peak is ensured, and through the intelligent double-drug-bin administration module and the precise metering pump, two drugs with the lowest effective dose are precisely delivered strictly according to the specific sequence of PGA first and CAI second; the time sequence control and precise quantitative administration based on the drug synergistic effect mechanism can ensure the synergistic antihypertensive curative effect, and can obviously avoid the high incidence rate adverse reaction caused by standard dosage combination.

The invention relates to the technical field of traditional Chinese medicines, in particular to a combustion type chronic obstructive pulmonary disease traditional Chinese medicine fumigant for targeted phlegm clearing, which is characterized in that the traditional Chinese medicine formula of the fumigant comprises platycodon grandiflorum, bulbus fritillariae cirrhosae, fructus perillae, flos farfarae, almond, radix stemonae and liquorice. The medicine effect is lasting and stable, the bulbus fritillariae cirrhosae or the green fritillary bulb is selected as a bulbus fritillariae cirrhosae source, the bulbus fritillariae cirrhosae and the green fritillary bulb have no obvious difference in phlegm clearing effect, but the bulbus fritillariae cirrhosae is slightly excellent in medicine effect durability, the medicine action time is prolonged, and the treatment effect is improved.

The invention relates to the technical field of medicines, in particular to application of huperzine A in treatment of beta-thalassemia. It is found for the first time that the anti-Alzheimer disease drug huperzine A can be directly combined with gamma-globin to inhibit degradation of gamma-globin through a ubiquitin-proteasome pathway, so that the stability of gamma-globin and the fetal hemoglobin level are improved; the abnormal erythropoiesis and hemolysis phenotype of the beta-thalassemia are improved under the condition of not changing the mRNA expression. Animal experiments show that huperzine A obviously improves hematocrit and the number of red blood cells, reduces the size distribution width of the red blood cells and the proportion of reticulocytes, relieves oxidative stress, hemolysis, splenomegaly and iron overload, and has no obvious liver and kidney toxicity. The invention creatively provides a new strategy for improving HbF by regulating and controlling protein homeostasis instead of transcriptional up-regulation, and provides a new drug action mechanism and application direction for treatment of beta-thalassemia and other hemoglobin diseases.

The invention provides a cough-relieving and phlegm-eliminating composition and a preparation method thereof. The cough-relieving and phlegm-eliminating composition is prepared from the following raw materials: anhydrous morphine, anhydrous codeine phosphate, apigenin, liquiritin, isoliquiritin, liquiritigenin, isoliquiritigenin, glycyrrhizic acid, trans-anethole, camphor and sodium benzoate. The composition further comprises a luffa stem extract, an atractylodes lancea rhizome extract and a radix ranunculi ternati bark extract. The cough-relieving and phlegm-eliminating composition provided by the invention has the advantages of few impurities, clear and remarkable drug effect and small side effect. Under the action of the core antitussive drug, three plant extracts of luffa stem, Atractylodes lancea and Ranunculus ternatus Thunb. Are creatively added, so that the phlegm eliminating capacity and the overall antitussive effect of the whole formula are remarkably enhanced. The cough-relieving and phlegm-eliminating composition disclosed by the invention realizes the synergistic interaction of '1 + 1 + 1gt, 3' on the core indexes of inhibiting the cough frequency, prolonging the cough latency period, promoting sputum excretion and the like, and realizes the cough-relieving and phlegm-eliminating effects of treating both symptoms and root causes through the multi-target-point and multi-mechanism synergistic effect.

The invention discloses a film-covered balloon double-cavity stomach tube and a preparation method thereof. The stomach tube comprises a double-cavity stomach tube body, a compliance balloon and a drug-loaded fiber film. The double-cavity stomach tube is provided with a main cavity for gastrointestinal drainage and a side cavity for balloon inflation and deflation; the compliance balloon is fixed to the esophageal section and expands and contracts through inflation and deflation of a side cavity. The outer surface of the balloon is coated with the drug-loaded fiber covering film, the drug-loaded fiber covering film is composed of coaxial drug-loaded nanofibers, a sheath layer of the drug-loaded fiber covering film is made of a blend of polylactic acid caprolactone and collagen, and a core layer of the drug-loaded fiber covering film is made of polylactic acid caprolactone dispersed with anti-inflammatory drugs and local anesthetic drugs. According to the preparation method, a drug-loaded fiber covering film is constructed on the surface of the balloon through a coaxial electrostatic spinning technology, drugs (such as dexamethasone and lidocaine) can be encapsulated in a nanofiber core layer, a sheath polymer material is used as a diffusion barrier, burst release of the drugs is effectively prevented, continuous and controllable release of the drugs at the esophageal diseased region is achieved, and the drug delivery effect is improved. The medicine action time is obviously prolonged; the curative effect is improved.

The present application relates to a kind of organ chip and deep learning-based anti-tumor compound prognosis drug efficacy prediction method, comprising the following steps: step 1, construct organ chip sample library;Step 2, construct wet experiment database;Step 3, data preprocessing, feature extraction and vectorization;Step 4, the construction of feature splicing model;Step 5, the training of feature splicing model, construct killing effectiveness prediction model, and carry out verification evaluation;Step 6, the training of feature splicing model, construct EC50 prediction model, and carry out verification evaluation;Step 7, the prediction of killing effectiveness and EC50 value.The present application combines organ chip technology and deep learning technology to predict the efficacy of anti-tumor drugs, realizes the fusion of dry and wet experiments, and at the same time as close as possible to the human body organ level systematic drug action, realizes high-throughput, automation, and avoids ethical risk data output.

The invention discloses a small-molecule active aldehyde scavenger-albumin coupling medicine as well as a preparation method and application of the small-molecule active aldehyde scavenger-albumin coupling medicine. The coupling drug comprises a) the small molecule active aldehyde scavenger compound or the derivative thereof and b) albumin, and the albumin comprises at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The medicine is further prepared into an ophthalmic preparation, the retention time of the medicine in the cornea is prolonged, the in-vitro active aldehyde removal efficiency of the medicine is improved to 1.5 times of that of NS-2, expression (larger than or equal to 50%) of a human corneal epithelial cell inflammatory factor IL-6 is remarkably inhibited, and irritation to eyes is avoided. Through the synergistic effect of long-acting slow release of the albumin carrier and targeted removal of NS, the technical defects that a traditional xerophthalmia medicine is short in effect and single in mechanism are overcome, and a definite clinical transformation value is achieved.

The invention relates to the field of material analytical chemistry and biochemistry, and provides a continuous batch pretreatment device and method for proteomics, glycoproteomics and phosphorylated proteomics samples. According to the continuous batch pretreatment device for the proteomics, glycoproteomics and phosphorylated proteomics samples, under the assistance of the filler, the whole process of protein denaturation, aggregation capture, enzymolysis and complete glycopeptide and phosphorylated peptide enrichment in biological samples can be achieved. Compared with a free solution method conventionally used in proteomics, the sample pretreatment method based on the device has the advantages that the sample treatment time can be effectively shortened, and continuous analysis of mass proteome, glycoprotein group and phosphorylated proteome of trace protein samples can be realized; the method is expected to be widely applied to the aspects of disease occurrence mechanisms, drug action mechanisms, clinical detection, biomarker discovery and the like.

The invention provides an application of a donepezil or gardenia jasminoides ellis-phellodendron amurense component in preparation of a cholinergic regulation-based immune liver injury resisting medicine, and belongs to the technical field of biological medicines. The pharmaceutical composition for resisting immunological liver injury is a donepezil component or a gardenia jasminoides ellis-phellodendron amurense component. The invention solves the problems of single action target and incomplete regulation and control mechanism of the existing immunological liver injury treatment medicine, provides a treatment scheme with anti-inflammatory, anti-oxidation, liver cell apoptosis inhibition and cholinergic system regulation and control functions, explores a brand new medical application of donepezil, verifies the liver protection effect of donepezil in immunological liver injury, and provides a new application of donepezil in immunological liver injury. The application limitation is broken through; the treatment effect of the Jashima component in an immune liver injury model induced by concanavalin A is defined, a dual regulation mechanism of inhibiting AChE expression and increasing alpha7 nAChR expression is disclosed, and the application scene is expanded; a multi-dimensional regulation and control network of cholinergic anti-inflammatory pathway-NF-kappa B inflammatory pathway-hepatocyte apoptosis is constructed, and a more efficient and comprehensive treatment strategy is provided for immunological liver injury.

The invention belongs to the technical field of biotechnology and medicine, and particularly relates to application of an Anapc11 gene / protein to screening of drugs for treating hyperuricemia-related multi-organ dysfunction. According to the invention, the Anapc11 gene is used as a molecular target or a drug action target, and is used for screening or preparing drugs for treating multi-organ dysfunction (including liver injury, testis dysfunction, intestinal barrier destruction and the like) caused by hyperuricemia. The invention provides a new application of the cell cycle promoting complex subunit E3 ubiquitin ligase Anapc11 gene, provides a new molecular target for treating hyperuricemia related multi-organ dysfunction, and breaks through the limitation that the existing uric acid reducing medicine is only limited to a metabolic link; a new direction and a good application prospect are provided for developing innovative medicines with organ protection effects.

The utility model provides a kind of hemostatic gauze ball with hemostatic medicament, it is related to gauze technical field, including sphere and medicament ball, the sphere includes absorbent cotton and gauze mesh belt, the absorbent cotton is spherical, the gauze mesh belt is wrapped in the outside of absorbent cotton, the inside center of absorbent cotton is equipped with inner cavity, the medicament ball is equipped inside inner cavity;The side of the sphere is equipped with hole, and hole is connected to the inside of inner cavity, the inside of hole is equipped with extrusion membrane;The utility model embeds medicament ball in sphere, without extra preparation medicine, when using, only need to lay under sphere to wound, extrude extrusion membrane, press the membrane of broken medicament ball, hemostatic medicament can flow out downwards, carry out quality to wound, it is convenient and fast to operate, it is convenient to use anytime, and when laying, by liquid guide wire core increase the speed of hemostatic medicament in inner cavity flowing downwards gauze mesh belt, with quick-dissolving effect, improve the efficiency of drug action.